A Phase 4 interventional study of Tramadol Hydrochloride/Dexketoprofen Trometamol and Tramadol Hydrochloride/Paracetamol in Acute Pain, sponsored by Menarini Group. Completed at 18 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-24.
Sponsored by Menarini Group · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing tramadol in Acute Pain — none open to participants now, 1 under way, none of them phase 3. Tramadol · Acute Pain.
Among the 10 studies testing tramadol in Acute Pain, this one is the 4th largest by enrollment, is one of 4 that started in 2016, is one of 3 in phase 4, and was the 2nd registered.
1,075 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
Browse Acute Pain studies →None of the 10 studies testing tramadol in Acute Pain is open now. The open studies under Acute Pain, anywhere →
Tramadol: first FDA approval 1995 (ULTRAM). What it is approved for, and how studies give it, is on its page →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 654 is above the median of 86 across 903 interventional studies indexed under Acute Pain.
Median enrollment 263 across the 10 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 9 most frequent:
Menarini Group is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Menarini Group has 4 studies filed under Acute Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing tramadol in Acute Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is aimed to evaluate the analgesic efficacy of TRAM.HCl/DKP.TRIS 75mg/25mg oral fixed drug combination in comparison with TRAM.HCl /paracetamol 75mg/650mg in the treatment of moderate to severe acute pain.
The present phase IV study is a randomised, double-blind, placebo and active-controlled, parallel group study in moderate to severe acute pain after removal of impacted lower third molar.
In this single-dose clinical trial patients are randomized to the following 3 treatment arms in a 2:2:1 ratio:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose; Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x \[37.5mg/325mg\] film-coated tablets, oral single dose.
Drug: Tramadol Hydrochloride/Dexketoprofen Trometamol · Drug: Placebo
Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x \[37.5mg/325mg\] film-coated tablets, oral single dose; Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose. .
Drug: Tramadol Hydrochloride/Paracetamol · Drug: Placebo
Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose; Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose.
Drug: Placebo
Drug pages: Tramadol · Dexketoprofen
Drug pages: Tramadol · Acetaminophen
TOTPAR6 (Total Pain Relief Over 6 Hours Post-dose)
TOTPAR calculated as the weighted sum of the PAR scores, measured according to a 5-point VRS (Verbal Rating Scale) from 0=no relief to 4=complete relief, over 6 hours post-dose (TOTPAR6). The TOTPAR6 ranges from a minimum of 0 to a maximum of 24.
Time frame: 6 hours post-dose
% of Patients Achieving 50% of Max TOTPAR
Percentage of patients who achieved at least 50% of the maximum TOTPAR at 8 hours. In the present trial the achievable TOTPAR over 8 hours ranges between 0 and 32."
Time frame: 8 hours post-dose
% of Patients Achieving at Least 30% of PI (Pain Intensity) Reduction Over 8 Hours Post-dose
Percentage of patients who achieve at least 30% of PI Reduction versus baseline Over 8 Hours Post-dose. Percentage change of PI is calculated using the baseline value minus the PI assessed at 8 hours post-dose divided for the baseline value, then multiplied for 100.
Time frame: 8 hours post-dose
Time to Confirmed FPPAR (First Perceptible Pain Relief)
Time to confirmed FPPAR (time to onset of analgesia) - i.e. time to FPPAR if confirmed by experiencing Meaningful Pain Relief (MPAR) FPPAR and MPAR assessed by using stopwatches: 1. 'first perceptible' PAR (FPPAR), i.e, at the moment they first felt any PAR whatsoever; 2. 'meaningful' PAR (MPAR, ie, when the relief from pain became meaningful to them)
Time frame: 2 hours post-dose
% of Patients Requiring RM (Rescue Medication)
Percentage of patients who required RM within the first over 8 hours post-dose.
Time frame: 8 hours post-dose
PGE (Patient Global Evaluation)
PGE of the study medication (measured according to a five-point VRS from 1 = poor to 5 = excellent) at 8 hours post-dose or whenever the patient uses Rescue Medication (RM).
Time frame: 8 hours postdose
This study was conducted in 18 centers across 5 European countries: Hungary, Italy, Poland, Spain and the United Kingdom. The clinical phase of the study started on 28th April 2016 (first screened patient) and concluded on 14th February 2017 (last patient out).
| Milestone | Tramadol/Dexketoprofen | Tramadol/Paracetamol | Placebo |
|---|---|---|---|
| Started | 261 | 262 | 131 |
| Completed | 260 | 261 | 131 |
| Not completed | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
TOTPAR calculated as the weighted sum of the PAR scores, measured according to a 5-point VRS (Verbal Rating Scale) from 0=no relief to 4=complete relief, over 6 hours post-dose (TOTPAR6). The TOTPAR6 ranges from a minimum of 0 to a maximum of 24.
| 5-point Verbal Rating Scale | Tramadol/Dexketoprofen | Tramadol/Paracetamol | Placebo |
|---|---|---|---|
| TOTPAR6 (Total Pain Relief Over 6 Hours Post-dose) | 13.0 ± 6.97 | 9.2 ± 7.65 | 1.9 ± 3.89 |
Percentage of patients who achieved at least 50% of the maximum TOTPAR at 8 hours. In the present trial the achievable TOTPAR over 8 hours ranges between 0 and 32."
| percentage of patients | Tramadol/Dexketoprofen | Tramadol/Paracetamol | Placebo |
|---|---|---|---|
| % of Patients Achieving 50% of Max TOTPAR | 47.7 | 35.5 | 5.3 |
Percentage of patients who achieve at least 30% of PI Reduction versus baseline Over 8 Hours Post-dose. Percentage change of PI is calculated using the baseline value minus the PI assessed at 8 hours post-dose divided for the baseline value, then multiplied for 100.
| percentage of patients | Tramadol/Dexketoprofen | Tramadol/Paracetamol | Placebo |
|---|---|---|---|
| % of Patients Achieving at Least 30% of PI (Pain Intensity) Reduction Over 8 Hours Post-dose | 40.0 | 35.5 | 9.9 |
Time to confirmed FPPAR (time to onset of analgesia) - i.e. time to FPPAR if confirmed by experiencing Meaningful Pain Relief (MPAR) FPPAR and MPAR assessed by using stopwatches: 1. 'first perceptible' PAR (FPPAR), i.e, at the moment they first felt any PAR whatsoever; 2. 'meaningful' PAR (MPAR, ie, when the relief from pain became meaningful to them)
| minutes | Tramadol/Dexketoprofen | Tramadol/Paracetamol |
|---|---|---|
| Time to Confirmed FPPAR (First Perceptible Pain Relief) | 21 (17 to 23) | 24 (20 to 27) |
Percentage of patients who required RM within the first over 8 hours post-dose.
| percentage of patients | Tramadol/Dexketoprofen | Tramadol/Paracetamol | Placebo |
|---|---|---|---|
| % of Patients Requiring RM (Rescue Medication) | 51.2 | 55.0 | 88.5 |
PGE of the study medication (measured according to a five-point VRS from 1 = poor to 5 = excellent) at 8 hours post-dose or whenever the patient uses Rescue Medication (RM).
| units on a scale | Tramadol/Dexketoprofen | Tramadol/Paracetamol | Placebo |
|---|---|---|---|
| PGE (Patient Global Evaluation) | 3.6 ± 1.1 | 2.8 ± 1.4 | 1.5 ± 0.9 |
Collected over Reported treatment emergent AEs (TEAEs) include events starting after administration of study drug on or after Day 1 and on or before end of study visit Day 6+/- 1.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tramadol/Dexketoprofen | 0/260 (0%) | 1/260 (0.4%) | 35/260 (13.5%) |
| Tramadol/Paracetamol | 0/262 (0%) | 0/262 (0%) | 40/262 (15.3%) |
| Placebo | 0/131 (0%) | 0/131 (0%) | 13/131 (9.9%) |
| Event | Tramadol/Dexketoprofen | Tramadol/Paracetamol | Placebo |
|---|---|---|---|
| SyncopeNervous system disorders | 1/260 | 0/262 | 0/131 |
| Event | Tramadol/Dexketoprofen | Tramadol/Paracetamol | Placebo |
|---|---|---|---|
| VomitingGastrointestinal disorders | 11/260 | 14/262 | 0/131 |
| DizzinessNervous system disorders | 6/260 | 13/262 | 0/131 |
| NauseaGastrointestinal disorders | 10/260 | 11/262 | 0/131 |
| Postoperative wound infectionInfections and infestations | 8/260 | 2/262 | 2/131 |
| Face oedemaGeneral disorders | 3/260 | 8/262 | 4/131 |
| SomnolenceNervous system disorders | 7/260 | 4/262 | 1/131 |
| Procedural painInjury, poisoning and procedural complications | 3/260 | 5/262 | 3/131 |
| HaematomaVascular disorders | 2/260 | 0/262 | 3/131 |
Intention-to-treat (ITT) population: all patients randomized.
| Age, Continuous(years) | Tramadol/Dexketoprofen | Tramadol/Paracetamol | Placebo | Total |
|---|---|---|---|---|
| Mean | 26.8 ± 7.48 | 27.1 ± 8.13 | 26.5 ± 7.67 | 26.9 ± 7.78 |
| Sex: Female, Male(Participants) | Tramadol/Dexketoprofen | Tramadol/Paracetamol | Placebo | Total |
|---|---|---|---|---|
| Female | 152 | 104 | 53 | 309 |
| Male | 108 | 158 | 78 | 344 |
| Race/Ethnicity, Customized(Participants) | Tramadol/Dexketoprofen | Tramadol/Paracetamol | Placebo | Total |
|---|---|---|---|---|
| White | 235 | 233 | 118 | 586 |
| Asian | 14 | 21 | 6 | 41 |
| Black or Afro-american | 7 | 3 | 6 | 16 |
| Other | 4 | 5 | 1 | 10 |
| Pain Intensity at Qualification(units on a scale) | Tramadol/Dexketoprofen | Tramadol/Paracetamol | Placebo | Total |
|---|---|---|---|---|
| Mean | 5.0 ± 1.19 | 4.9 ± 1.12 | 4.8 ± 1.10 | 4.9 ± 1.14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2016 to primary completion in Feb 2017, 10 months.
Results were first posted in Mar 2021, 4 years 1 month after primary completion.
Of 84 phase 4 interventional studies under Acute Pain, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tramadol · Dexketoprofen